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Abstract: In healthy tissue, a wound initiates an inflammatory response characterized by the 
presence of a hematoma, infiltration of inflammatory cells into the wound and, eventually, wound 
healing. In pathological conditions like diabetes mellitus, wound healing is impaired by the 
presence of chronic nonresolving inflammation. p38 mitogen-activated protein kinase (MAPK) 
inhibitors have demonstrated anti-inflammatory effects, primarily by inhibiting the expression 
of inflammatory cytokines and regulating cellular traffic into wounds. The db/db mouse model 
of type 2 diabetes was used to characterize the time course of expression of activated p38 
during impaired wound healing. The p38α-selective inhibitor, SCIO-469, was applied topically 
and effects on p38 activation and on wound healing were evaluated. A topical dressing used 
clinically, PromogranTM, was used as a comparator. In this study, we established that p38 is 
phosphorylated on Days 1 to 7 post-wounding in db/db mice. Further, we demonstrated that 
SCIO-469, at a dose of 10 µg/wound, had a positive effect on wound contraction, granulation 
tissue formation, and re-epithelialization, and also increased wound maturity during healing. 
These effects were similar to or greater than those observed with PromogranTM. These results 
suggest a novel approach to prophylactic and therapeutic management of chronic wounds 
associated with diabetes or other conditions in which healing is impaired.
Keywords: p38 MAPK ihibition, diabetic wound healing, db/db mouse, nonresolving healing, 
PromogranTM
Introduction
Chronic wounds are defined as those that fail to heal within an expected time period, 
and are characterized by impairment of wound closure and contraction rates, re-
epithelialization and granular tissue formation which is characterized by the presence of 
chronic nonresolving inflammation. Thus, agents capable of limiting wound inflamma-
tion may prove to be effective therapies for chronic wounds. Impaired wound healing is a 
well-documented phenomenon in diabetes mellitus.1,2 Experimental and clinical wound-
healing studies have revealed that the hyperglycemic state in diabetes is accompanied 
by impaired repair capacity at almost all stages of wound healing, including cellular 
migration, cellular proliferation, tensile strength of collagen, capillary growth, and meta-
bolic activity within the granulation tissue.3 Available literature indicates that several 
phases of the healing process – inflammation, cellular proliferation, matrix formation, 
and remodeling – are controlled by cytokines and growth factors. The inflammatory 
cytokine TNFα is associated with nonresolving inflammation and deficient healing.4–8
In diabetes, a delaying factor in wound healing is chronic nonresolving 
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as well.9,10 Although the current treatment in diabetic wound 
management involves debridement, topical antibiotics, 
and a state-of-the-art dressing, complications from chronic 
wounds still arise. Indeed, 60% of all nontraumatic 
amputations performed in the United States are a direct 
result of diabetes.11 Development of a more effective treat-
ment for chronic diabetic wounds is imperative. Hinchliffe 
and colleagues systematically reviewed the effectiveness 
of interventions to enhance the healing of chronic ulcers of 
the food in diabetes recently.12 In addition, limiting wound 
inflammation may improve treatment of chronic wounds, 
and systemic or topical administration of p38 mitogen-
activated protein kinase (MAPK) inhibitors have been 
shown to reduce skin inflammation.13,14 α-selective p38 
MAPK inhibitors such as SD-169, SD-282, and SCIO-469 
inhibit the activity of a wide variety of inflammatory cells, 
including neutrophils, monocytes, macrophages, B and CD4+ 
T cells, and endothelial cells. They also limit production of 
HSP-27, pro-inflammatory cytokines, vascular endothelial 
growth factors, interleukin-6, tumor necrosis factor-α 
(TNFα) and IL-1β, as well as TNFα activity and HSP-27 
phosphorylation.15–18 All of these inflammatory mediators are 
thought to play essential roles in wounds with nonresolving 
inflammation and it is worth pursing the therapeutic value of 
a α-selective p38 MAPK inhibitor like SCIO-469 in wound 
healing settings associated with conditions in which healing 
is impaired such as type 2 diabetes.
The db/db mouse is an animal model of diabetes mellitus, 
and inflammation-mediated experimental wound progression 
in the model mimics what is seen in diabetic humans.19,20 
Accordingly, we used this model to evaluate the efficacy of 
topical administration of a p38 kinase inhibitor compared to a 
Johnson and Johnson product used topically for the treatment 
of chronic wounds. Promogran™ (oxidized regenerated 
cellulose/collagen; Johnson and Johnson Medical, Ltd., 
Ascot, UK) is used clinically as a topical dressing for chronic 
wounds. It binds matrix metalloproteases and protects growth 
factors in chronic wound fluid, promoting an environment 
that attracts cells, supports tissue growth factors, and 
facilitates tissue granulation.21 Hart and colleagues reported 
delayed healing in diabetic db/db mice when compared to 
their nondiabetic lean littermates (db/+) and showed that 
topical PromogranTM accelerated healing in diabetic db/db 
mice as compared to nondiabetic littermates,22 making it an 
appropriate comparator and positive control.
Since topical administration offers some advantages over 
the systemic route, such as low risk of systemic toxicity 
and potentially lower amounts of drug required, we studied 
topical therapeutic application of the p38 MAPK inhibitor, 
SCIO-469, at doses of 0.1, 1, and 10 µg/wound for 14 days 
using PromogranTM as a positive control, and found that 
SCIO-469 (at 10 µg/wound) yielded significant therapeutic 
benefit in db/db mice by day 7 of the treatment (unpublished 
observations). In the present communication, we report on the 
involvement of p38 MAPK α-signaling in diabetic wounds 
and describe our results in treating wounds with topical 
SCIO-469 in diabetic db/db mice.
Materials and methods
chemical description of ScIO-469
SCIO-469 is an indole-5-carboxamide and an ATP-competitive 
inhibitor of p38 kinase. It is a small-molecule, orally active 
inhibitor of p38α MAPK (Scios, Inc., Fremont, CA).
SCIO-469 potency and specificity
SCIO-469 and its structurally and pharmacologically similar 
analogues SD-282 and SD-169 and have demonstrated 
anti-inflammatory and arthritis-modifying properties and are 
known to influence the cytokines involved in inflammatory 
disorders.15,16 They reversibly inhibit kinase activity of p38 
MAPKα, an intracellular enzyme that mediates cellular 
responses to inflammatory stimuli.23 Inhibitory concentration 
of 50% (IC50) of SCIO-46924,25 against the human p38 MAPKs 
(α, β, γ, and δ isoforms) were performed in duplicate using 
ELISA assays adapted from published methods. SCIO-469 
demonstrates ∼14-fold selectivity for p38α MAPK (IC50 
values of 0.0016 and 0.0011 µM) compared with p38β 
MAPK (IC50 values of 0.023 and 0.022 µM), whereas 
inhibition of p38γ MAPK and p38δ MAPK was less than 
50% even at concentrations of 10 µM. When tested in vitro 
at a concentration of 10 µM, SCIO-469 demonstrated no 
inhibitory activity against a panel of other kinases, including 
extracellular signal-regulated kinase 2, c-Jun NH2-terminal 
kinase-1, and MAPK-activated protein kinase-2. In addition, 
SCIO-469 demonstrates no effect on the activity of purified 
cyclooxygenase-1 (COX-1) or COX-2 enzymes.
Dressings and reagents
PromogranTM, Pad of Release, and Bioclusive Dressing were 
purchased from Johnson and Johnson Medical Ltd (Ascot, 
UK). For the phosphorylated p38 measurements, primary 
rabbit polyclonal antibody was purchased from Santa Cruz 
Biotechnology (Cat. No. SC-7975-R; Santa Cruz, CA, USA), 
and the secondary antibody (goat anti-rabbit biotinylated IgG) 
was purchased from Chemicon International Inc. (Cat. No. 
AP187B; Temecula, CA, USA).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 93
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Animals
Diabetic mice (C57BLKs/Bom db/db; B&M, Denmark) with 
sustained hyperglycemia (blood glucose ∼400 mg/dl) for 
several weeks which are prone to impaired wound healing 
and their lean littermates or nondiabetic mice (C57BLKs/
Bom db/+; B&M) aged approximately 16 weeks were used 
in this study. On the first day of the study period, mice were 
housed in individual cages in an environment maintained 
at an ambient temperature of 23 °C with 12-hour light/dark 
cycles. They were provided with food (standard rodent diet) 
and water ad libitum. All animal procedures were approved 
by our institutional committee for the care and use of animals 
in research in accordance with the guidelines of Scios, Inc., 
USA and Johnson and Johnson Wound Management, UK.
creation of full thickness  
experimental wounds
Mice  were  anesthetized  (isoflurane  and  air)  and 
shaved. A single, standardized full-thickness wound 
(7.5 mm  × 7.5 mm) was created in the flank skin of 
each experimental mouse. Wounds were treated with 
PromogranTM (Johnson and Johnson Medical Ltd) applied 
as 1 cm × 1 cm squares throughout the study according to 
manufacturers instructions. All wounds were secondarily 
dressed with a 1.5 cm × 1.5 cm Pad of Release (Johnson 
and Johnson Medical Ltd). The release pad was held in 
place using a circumferential band of occlusive film dressing 
(Bioclusive; Johnson and Johnson Medical Ltd). Mice were 
re-anesthetized, and treatments were reapplied on days 0, 1, 
2, 4, and 7 post-wounding. Immediately after wounding and 
subsequently on days 2, 4, and 7, all wounds were digitally 
photographed with a calibration/identity plate. On day 7 of 
the study, animals were euthanized.
Time-course of phosphorylated  
p38 levels in wounds
As described above, a full thickness wound was created on 
15 diabetic mice having blood glucose levels around 400 
mg/dl. Wounds were immediately treated topically with 50 
µl of citrate buffer at pH 4 (covering a 1 cm × 1 cm area) 
to provide moisture to the wound area. This treatment also 
served as a vehicle control group for the study described 
in the next section. The wounds were secondarily dressed 
with a 1.5 cm × 1.5 cm Pad of Release as described earlier. 
The bandages were changed on days 4 and 7. At dressing 
change time points, a few drops of sterile saline were added 
to dressings as necessary to minimize the occurrence of 
re-injury. Food was made available after recovery from each 
procedure. Glucose monitoring was performed on all mice 
prior to study inception and prior to the day of necropsy. 
On days 0, 1, 2, 4, and 7 of the study, three mice per time 
point were euthanized. Each wound with surrounding normal 
tissue was excised and subsequently fixed in 10% formalin 
for the measurement of phosphorylated p38 by immunohis-
tochemistry.
Immunohistochemistry
Immunohistochemical staining for phospho p38 was 
performed as detailed in our earlier communication.15 
The primary antibody used in this study was rabbit 
phospho-p38 polyclonal antibody diluted at 1:50 (Cat. No. 
Sc-7975-R; Santa Cruz Biotechnology). The secondary 
antibody used for phospho-p38 was goat anti-rabbit bio-
tinylated immunoglobulin G (IgG) (Cat. No. AP187B; 
Chemicon International, Inc.) diluted at 1:2000, and the 
negative control in this case was normal rabbit IgG. Phospho-
p38 immunohistochemistry analysis was evaluated in a 
blinded manner by the number of the positively stained cells 
in 10 different regions of the wound, averaged and scored as: 
0 = none; 1 = mild (around 25% positively stained cells per 
field); 2 = moderate (around 50% positively stained cells per 
field); and 3 = severely (around 75% positively stained cells 
per field) positively phosphor-p38 in the wound.
effect of ScIO-469 on phosphorylated 
p38 levels in wounds
In parallel with the p38 phosphorylation studies described 
above, 15 diabetic mice were wounded as described earlier 
and treated with SCIO-469. Soon after the wounding, mice 
received a topical application of 10 µg of SCIO-469 in 
50 µl of citrate buffer at pH 4. Following the application of 
SCIO-469, wounds were dressed secondarily as described 
above. Mice were re-anesthetized and SCIO-469 treatment 
re-applied on days 1, 2, 4, and 7 post-wounding. As described 
earlier, on days 0, 1, 2, 4, and 7, three mice per time point 
were sacrificed, and wounds were processed for the measure-
ment of phosphorylated p38 as described above.
effect of ScIO-469 on wound  
healing in db/db mice
Thirty-two female diabetic mice with blood glucose levels 
around 400 mg/dl and eight female nondiabetic mice (db/+) 
were wounded as described above. Diabetic mice were 
divided into four treatment groups as follows: mice in group 1 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 94
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were sacrificed soon after the wounding; group 2 received 
50 µl of vehicle control (citrate buffer, pH 4), group 3 
received Promogran™ (positive control); and group 4 received 
10 µg of SCIO-469 in 50 µl of citrate buffer solution topi-
cally. Wounds were secondarily dressed as described above. 
Mice were re-anesthetized, and treatments were reapplied on 
days 1, 2, 4, and 7 post-wounding. Body weights and blood 
glucose levels were monitored on days 0 and 7 of the study. 
On day 7 of the study, mice were euthanized. Their wounds 
and the surrounding normal tissue were excised and subse-
quently fixed in 10% formalin and processed as described 
above. Eight nondiabetic mice (db/+) received identical 
experimental manipulations and treatments.
Photographic assessment for wound closure
Immediately after wounding and on days 2, 4, and 7, all 
wounds were digitally photographed with a calibration/
identify plate.
Assessment of wound closure
Wound assessments were performed at every bandage 
change, and macroscopic observations of wound healing 
were recorded as follows: presence and degree of inflam-
mation (slight, moderate, extreme); edema (slight, moderate, 
extreme); erythema (slight, moderate, extreme); induration 
(yes, no); amount of exudate (slight, moderate, extreme); 
wound-bed environment (moist/dry); re-injury (slight, mod-
erate, extreme); and other miscellaneous comments.
Histological assessment of wound healing
Histological evaluations were undertaken blinded manner 
on representative hematoxylin and eosin stained sections of 
each wound. Evaluation parameters included wound width, 
re-epithelialization, granular tissue formation, and cellular 
profiles as described below.
Wound width
Wound width was measured as the distance between normal 
dermal tissues (wound curvature was taken into account). 
Three wound-width measurements (from three replicate 
sections) were taken, and the mean wound width was calcu-
lated for each wound (Figure 1A). Image Pro image analysis 
software (version 4.1.0.0; Media Cybernetics, Bethseda, 
MA, USA) was used to calculate wound closure from wound 
images in each of the experimental groups over time.
re-epithelialization
Percentage re-epithelialization was measured from three 
replicate sections of each wound. The extent of neo-epithelial 
tissue coverage was defined as the distance from the leading 
edge of the epithelial tongue (over the wound) to the edge 
of the first intact hair follicle (in marginal tissue). A mean 
re-epithelialization score was calculated (see below) from 
three replicate sections.
  %RE epithelialization
b d
b c d
− = ×
+
+ +
 
where “b + d” stands for neo-epithelialized coverage, and 
“c” stands for nonepithelialized tissue (open wound) (see 
Figure 1A).
Granulation tissue
Granulation tissue formation was scored in terms of the 
volume of the wound void occupied with granulation tissue 
(Figure 1B). A five-point, semiquantitative scoring system 
was devised for the purpose of this study with 1 indicating 0% 
to 20% wound void filled with granulation tissue; 2 indicating 
20% to 40% of wound void filled with granulation tissue; 3 
indicating 40% to 60% wound void filled with granulation 
tissue; 4 indicating 60% to 80% of wound void filled with 
granulation tissue; and 5 indicating 80% to 100% of wound 
void filled with granulation tissue. Three replicate sections of 
each wound were assessed for granulation tissue formation.
Cellular profiles in the wound tissue
All wounds were assessed in terms of the type of cell 
predominating within wound tissue (Figure 1C). Cells were 
classified as either inflammatory cells (eg, neutrophils, mac-
rophages, lymphocytes) or proliferative cells (eg, fibroblasts, 
endothelial cells) by microscopic examination of tissue slides. 
The relative contribution of inflammatory and proliferative 
cells to the cellular population of granulation tissue was scored 
with the aid of a five-point semiquantitative system with 1 
indicating highly inflammatory; 2 indicating predominantly 
inflammatory; 3 indicating equivalence; 4 indicating predomi-
nantly proliferative; and 5 indicating highly proliferative. In 
addition to being a score of cell type, this scale was read as a 
score of “wound maturity,” with less mature wounds (being 
primarily populated by inflammatory cells) achieving lower 
scale readings, and more mature wounds (primarily populated 
by proliferative cells) achieving higher readings. The score 
recorded for a given wound reflected the predominant cellular 
profile of the tissue within the wound void.
Statistical analysis
Nonparametric analysis (Kruskal–Wallis multivariate analysis 
followed by an ad hoc two-sample Mann–Whitney U-test Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 95
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analysis) was used to test the significance of any intergroup 
differences in wound closure, re-epithelialization, and granula-
tion tissue deposition. The Student’s t-test was used to test the 
significance in cases of phosphorylated p38 measurements.
Results
p38 was phosphorylated in the wounded 
skin of db/db mice
Grading of antiphospho-p38-stained wound sections showed 
that p38 activation in the wounded skin peaked at days 1 to 2 
and then displayed a reduction of phosphorylation (black bars 
in Figure 2). As compared to unwounded tissue, phospho-p38 
increased significantly and peaked on day 1 (p  0.001) 
soon after wounding; it remained at peak plateau levels at 
day 2 (p  0.001), followed by a progressive decrease on 
days 4 and 7.
ScIO-469 reduced phosphorylated  
p38 in the wounded skin of db/db mice
Topical application of SCIO-469 reduced the level of 
phospho-p38 during wound healing in a time dependent 
manner (cross hatched bars in Figure 2). As in Figure 2, 
phosphorylated p38 levels increased significantly in the first 
two days of wound healing when compared to day 0, and 
SCIO-469 significantly reduced those levels compared to the 
vehicle group by day 2 (p  0.001).
A
B
C
Figure 1 Histological assessments/scoring methods of wound healing in db/db mice.    A single, standardized full-thickness wound (7.5 mm × 7.5 mm) was created in the flank 
skin of each experimental db/db mouse. (A) Wound width measurement method.   Wound width was measured as the distance between normal dermal tissues (wound curvature 
was taken into account) where “a” stands for margin to margin separation (wound width), “b + d” stands for neo-epithelial coverage, and “c” stands for nonepithelialized tissue 
(open wound).   Three wound-width measurements (from three replicate sections) were taken and mean wound width was calculated for each wound. (B) Granular tissue 
formation: upper panel represents 0% to 20% of wound void filled with granulation tissue; lower panel represents 80% to 100% of wound void filled with granulation tissue. 
(C) Cell type or cellularity scoring system.   The left panel represents a highly inflammatory condition and the right panel shows a highly proliferative condition.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 96
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Figure 2 ScIO-469 reduced phosphorylated p38 in diabetic wounds. Immunohistochemical staining for phospho-p38 (phospho p38). In vehicle treated group, phospho-p38 
peaked by day 1 post-wounding (p  0.001), plateaued by day 2 (*p  0.001) and progressively decreased at days 4 and 7 when compared to data collected soon after wounding 
on day 0. SCIO-469 treatment significantly reduced levels of phospho-p38 on day 2 (#p  0.001). Reductions at day 1 and day 7 were substantial but not statistically significant. 
Black bars-vehicle group; cross-hatched bars-ScIO-469, 10 µg/wound/treatment.   Values are reported as the mean ± Se; n = 5.
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There was no significant change in body weight in the 
SCIO-469 treated group when compared to the vehicle 
control group.
ScIO-469 accelerated wound 
healing in db/db mice
As per the digital photographic data, the rate of wound 
closure was confirmed to be dependent on mouse genotype, 
with db/db diabetic mice healing more slowly than db/+ 
nondiabetic littermates. Citrate buffer-treated wounds on 
nondiabetic mice were statistically smaller (p  0.05) than 
similarly treated wounds on diabetic mice at each time point 
(Figure 3A). The positive control treatment, Promogran™, 
significantly accelerated wound healing in diabetic mice at all 
time points (Figure 3B). SCIO-469-treated diabetic wounds 
were also found to be statistically smaller than vehicle-treated 
wounds at all time points (Figure 3C): day 2 (p  0.02), 
day 4 (p  0.01), and day 7 (p  0.01). The rate of closure 
of diabetic wounds treated with SCIO-469 was smaller 
(p  0.01) when compared to the vehicle-treated group and 
superior to the Promogran™-treated groups. Its superiority 
over Promogran™ is statistically not significant (Figure 3D).
ScIO-469 reduced wound width
Histology data revealed that diabetic wounds treated with 
SCIO-469 had a significantly smaller mean wound width 
than diabetic wounds treated with citrate buffer (p  0.03), 
suggesting that SCIO-469 promoted wound contraction 
in db/db mice (Figure 4A). SCIO-469 was as effective as 
Promogran™ and produced wound widths similar to those 
seen in nondiabetic mice (db/+) at relevant time points (data 
not shown).
ScIO-469 accelerated re-epithelialization
As per the histology data, topical application of SCIO-469 
to wounds in diabetic mice resulted in statistically signifi-
cant increases in wound re-epithelialization relative to the 
vehicle group (p  0.02; Figure 4B). SCIO-469 effects were 
comparable to those seen with Promogran™ and simulated 
re-epithelialization patterns of nondiabetic mice (data not 
shown).
ScIO-469 increased granulation
Histological analysis showed that treatment of diabetic 
wounds with SCIO-469 increased formation of granula-
tion tissue relative to the vehicle-treated group at day 7 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 97
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(Figure 4C), and was comparable to effects seen with 
Promogran™ treatment, with similar granulation levels as 
those seen in nondiabetic mice.
SCIO-469 reduced inflammatory  
cell infiltration into the wound
Histological analysis also showed that treatment of diabetic 
wounds with Promogran™ had no impact on cellular maturity 
within wound tissues compared to vehicle treatment alone. 
Promogran™ did not appear to modulate inflammatory or 
proliferative cell presence within diabetic wounds. In contrast, 
topical application of SCIO-469 to diabetic wounds was associ-
ated with a significant increase in proliferative cells over inflam-
matory cells as compared to vehicle (p  0.02) or Promogran™ 
(p  0.01) treatments (Figure 4D); these data are similar to 
those collected from nondiabetic mice (data not shown).
The gross observational data collected on wound healing 
(degree of inflammation, edema, erythema, induration, 
amount of exudate, wound-bed environment, and re-injury/
secondary wounds) (data not shown) supported the significant 
improvements in wound width, re-epithelialization, 
granulation tissue formation, and wound maturity seen with 
topical application of SCIO-469 compared to vehicle alone.
Discussion
In this study, we confirm results showing that citrate 
buffer-treated wounds healed significantly more slowly in 
db/db mice than in similarly treated wounds of nondiabetic 
littermates (db/+), and confirmed that Promogran™ treatment 
accelerated wound closure in diabetic db/db mice. Next, we 
measured levels of the phosphorylated (activated) form of 
p38 in the presence and absence of the p38α MAPK-selective 
inhibitor, SCIO-469, in the skin for a period of 7 days 
post-wounding. Phosphorylated p38 was present after 
wounding, with peak levels on days 1 and 2, declining 
to near baseline by day 7 in db/db mice with sustained 
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Figure 3 ScIO-469 accelerated wound healing in db/db mice. (A) Digital photographic imaging data showed that wound healing was significantly (*p  0.001) impaired in 
the diabetic db/db mice (open circles) when compared to the nondiabetic db/+ mice (filled circles): (B) establishing the suitability of this model. Promogran™ (open squares) 
significantly (*p  0.05) accelerated wound healing in db/db mice at all time points when compared with the db/db mice (vehicle-treated group) (open circles); (C) ScIO-469 
(open triangles) significantly (*p  0.01) accelerated wound closure in db/db mice at all time points when compared to the vehicle-treated group (open circles); (D) ScIO-
469-treated db/db wounds (solid bar) were significantly smaller (ie, reduced % of wound area remaining) on day 7 (**p  0.01) when compared to the vehicle treated group 
(dotted bar) and superior to the Promogran™-treated group (*p  0.05 when compared to the vehicle-treated group) (open bar).   The hatched bar represents wound healing 
in nondiabetic mice. Values are reported as the mean ± Se; n = 8.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 98
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hyperglycemia. In contrast, phosphorylated p38 was not 
present at any detectable levels on any day in lean litter mates 
(nondiabetic mice) (Medicherla, unpublished results, 2006).
SCIO-469 accelerated wound healing when applied 
topically and was associated with significantly lower peak 
levels of phosphorylated p38 (day 2). The current studies do 
not differentiate between reduced levels of total p38 and/or 
reduced proportion of p38 which is phosphorylated (acti-
vated). Histological studies showed that SCIO-469 treatment 
decreased wound width and increased granulation tissue 
formation and re-epithelializaiton by the end of the study (day 
7 post-wounding). These outcomes were comparable or supe-
rior to those obtained with Promogran™ treatment. Unlike 
Promogran™, application of SCIO-469 to diabetic wounds 
increased cellular wound maturity: the ratio of proliferative 
cells over inflammatory cells. Thus, SCIO-469 significantly 
inhibited infiltration of inflammatory cells into the wound 
(Figure 4D) which suggests limiting wound inflammation 
improves wound healing.
Regulation of p38 activation appears to be critical during 
wound healing in db/db mice. Since SCIO-469-medi-
ated inhibition of p38 phosphorylation in neutrophils and 
macrophages was associated with significant improvements 
in wound healing, SCIO-469 may accelerate wound healing 
by blocking the p38 MAPK signaling pathway. This 
explanation is consistent with our unpublished observations 
that SCIO-469 significantly decreases neutrophil infiltration 
into the hemorrhagic skin in a lipopolysaccharide-induced 
skin inflammation model, and lowers macrophage numbers 
in a smoke-induced mouse model of chronic obstructive 
pulmonary disease (COPD) (S. Medicherla, unpublished 
observations, 2006). Our data do not address the relative 
Figure 4 Histological assessments of wound healing. nondiabetic mice (hatched bars), vehicle-treated db/db mice (dotted bars), Promogran™-treated db/db mice (open bars), 
SCIO-469-treated db/db mice (solid bars). Like Promogran™, SCIO-469 significantly (*p  0.03) accelerated wound healing by decreasing wound width (A), increasing percent 
of re-epithelialization (B; *p  0.02) and increasing granular tissue formation (C; *p  0.02) when compared to the vehicle-treated group. Unlike Promogran™, ScIO-469 also 
significantly increased wound maturity/cellularity (D) ie, prevalence of proliferative cells over inflammatory cells (#p  0.02) and it is statistically significant when compared 
to the Promogran™ group (*p  0.01) Values are reported as the mean ± Se; n = 8.
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roles of low-density lipoprotein,26 advanced glycation 
end-products,27 free fatty acids,28 diacylglycerol,29,30 heat 
shock protein-27,15,30 tumor growth factor-β,30 or macrophage-
derived TNFα31 in this model. It is possible that one, many, or 
all of these factors together can activate the p38 MAPK path-
way, and that SCIO-469 treatment may inhibit the effects of 
these agents on inflammatory responses and delayed wound 
healing. The data in the present study suggest that SCIO-469 
inhibits nonresolving inflammation in diabetic wounds via the 
p38 MAPK signaling pathway. This is an anti-inflammatory 
action not seen or expected with Promogran™. The results 
suggest that SCIO-469 may be a superior therapeutic agent 
to manage wounds in those with impaired healing ability and 
may be a useful addition to Promogran™ therapy.
In summary, we report that SCIO-469, an α-selective p38 
MAPK inhibitor, accelerates wound healing by inhibiting 
nonresolving diabetes-induced inflammation in a db/db 
mouse model of impaired wound healing. These results 
may have bearing on current prophylactic and therapeutic 
protocols for treating wounds in types 1 and 2 diabetics 
and in other pathological conditions in which nonresolving 
inflammation is a primary feature.
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